Loading…
← CockpitCompetitor Analysis › 2877.HK China Shineway Pharmaceutical Group LimitedOpen in the cockpit ↗

China Shineway Pharmaceutical Group Limited2877.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Other
Momentum strong 76
Mkt cap
$760M
US dollars, full cap
Free float
34%
of shares outstanding
$/day
$904,263
20-day average traded
Fwd P/E
7.6×
forward earnings
ROIC−WACC
+45.6 pp
WACC 8.1%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · HKDHK$7.92
1D+1.5%
1W+2.0%
1M+6.0%
3M-1.0%
6M-7.8%
YTD-8.0%
1Y-13.9%
ATR %2.5%
52w lowhigh24.4% off high

What China Shineway Pharmaceutical does

Employees: 2,822

China Shineway Pharmaceutical at a glance

Size China Shineway Pharmaceutical (2877.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $760M, the 649th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$7.92 on 18 Nov 2026.

Performance Over six months the shares fell 7.8%, against -19.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 17.7% over the last twelve months (peer median +0.5%); the operating margin is 24.5% (peer median 7.2%).

Valuation It trades at 7.6× forward earnings against a peer median of 20.7× (cheapest of 13).

Capital Return on invested capital runs 45.6 points above its cost of capital (8.1% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 20262877.HK 93Peer median 81
Six months, rebased to 100: China Shineway Pharmaceutical against the median of its 20 peers (local-currency closes).

China Shineway Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$2.97BHK$3.40BHK$4.10BHK$4.99BHK$4.59B
Revenue growth—-17%-18%+9%—
Gross profitHK$2.12BHK$2.46BHK$3.07BHK$3.75BHK$3.42B
EBITDAHK$893MHK$817MHK$981MHK$1.14BHK$898M
Net incomeHK$902MHK$1.03BHK$911MHK$1.07BHK$840M
Free cash flowHK$1,000MHK$1.28BHK$1.07BHK$939MHK$1.24B
Capital expenditureHK$197MHK$215MHK$152MHK$159MHK$151M
Total debtn/aHK$373MHK$369MHK$332MHK$8.36M

Quarterly statements and history in the cockpit →

China Shineway Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%3007916004883000396032620460002562300158PHN0775002219300261APN301507000756AVBP0022750026440024122142CRON2877.HK6-month return →1-month return →
Up and to the right = strong over both horizons. China Shineway Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×200×400×3007916032620460PHN002219300261APN30150700075621422877.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Shineway Pharmaceutical is the large dot.

China Shineway Pharmaceutical competitors and peer comparison

How China Shineway Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Shineway Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure2877.HKPeer medianRank in peer set
1-month return+6.0%-9.3%2nd highest of 21
6-month return-7.8%-19.1%6th highest of 21
Distance from 52-week high-24.4%-40.9%4th highest of 21
Revenue growth (TTM)-17.7%+0.5%2nd lowest of 20
Operating margin24.5%7.2%3rd highest of 21
Forward P/E7.6×20.7×cheapest of 13
ROIC minus cost of capital+45.6 pp-0.1 pphighest of 20
Net debt / EBITDA-9.4×-1.3×2nd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%45.4×19.1%+12.1%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%20.0×0.5%+7.9%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%n/an/an/a
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%n/a15.4%+6.5%
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%n/a1.4%+7.0%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%

Questions

Which companies are China Shineway Pharmaceutical's closest peers?
The cockpit's peer set: Sirio Pharma (300791.SZ), Tianjin Tianyao Pharmaceuticals (600488.SS), Shanghai Kaibao Pharmaceutical (300039.SZ), TSI (603262.SS), Sihuan Pharmaceutical (0460.HK), Brother Enterprises (002562.SZ), Shanxi Zhendong Pharmaceutical (300158.SZ), PharmaNutra (PHN.MI).
Is China Shineway Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 7.6× against a peer median of 20.7×, cheapest of 13 in its peer set.
How has China Shineway Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -7.8% against -19.1% for the median peer; over one year -13.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.